Genomma Lab stock costs EUR 0.63 with USD 0.7 billion market value

Published on 10/09/2026 at 19:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Genomma Lab stock is EUR 0.63 on October 9, 2026, unchanged from EUR 0.63. Market value is USD 0.7 billion, with a P/E of 7.9.

Key points in brief

Genomma Lab stock was unchanged at EUR 0.63 at Lang & Schwarz on October 9, 2026.
Market capitalization was USD 0.7 billion and the P/E ratio was 7.9 as of October 8, 2026.
Third-quarter results are scheduled for October 21, 2026, after the Mexican Stock Exchange close.

Genomma Lab, MX01LA010006, Illustration mit AI erstellt.

Genomma Lab stock (ISIN MX01LA010006) was trading at EUR 0.63 at Lang & Schwarz on October 9, 2026 at 7:46 p.m. CEST, unchanged versus the prior close of EUR 0.63 on October 8, 2026. Its USD 0.7 billion market capitalization gives the price report a clear valuation anchor.

Price stays unchanged after hours

Lang & Schwarz quoted a bid of EUR 0.63 and an ask of EUR 0.64 at the same October 9, 2026 timestamp. The unchanged price keeps the spread at EUR 0.01, a small but visible gap between the available buying and selling quotes.

Genomma Lab is listed on the Mexican Stock Exchange under the LABB symbol, according to Morningstar. The listing gives German investors a euro indication through Lang & Schwarz while the home-market quotation remains in Mexican pesos.

Valuation offers a second anchor

The finance quote dated October 8, 2026 put Genomma Lab's market capitalization at USD 0.7 billion, with a P/E ratio of 7.9 and a dividend yield of 6.00 percent. Those figures describe the valuation snapshot separately from the unchanged euro price.

Genomma Lab operates in healthcare, with specialty and generic drug manufacturing as its industry classification. Its product portfolio covers over-the-counter medicines and personal care products sold across Mexico and international markets, giving the company exposure to both health and consumer demand.

Comparison with peers

Genomma Lab: unchanged, P/E 7.9, market capitalization USD 0.7 billion

Kenvue (USD): plus 0.1 percent, P/E 20.4, market capitalization USD 34.1 billion

Kimberly-Clark (USD): plus 0.4 percent, P/E 16.7, market capitalization USD 32.6 billion

October 21 is the next date

According to Morningstar on October 1, 2026, Genomma Lab will publish third-quarter 2026 earnings on October 21, 2026, after the Mexican Stock Exchange close. The company scheduled its conference call for October 22, 2026, at 11:00 a.m. Mexico City time.

On September 17, 2026, Genomma Lab's investor-relations page listed a CEO transition as part of a new stage for the company, linking the management change to its ongoing operating program.

Euro quote remains the reference

For German investors, the unchanged EUR 0.63 Lang & Schwarz indication is the central market figure for October 9, 2026. The next scheduled results date provides the clearest calendar marker for a new operating comparison.

The further course of trading is shown by the continuously updated real-time quote of Genomma Lab stock.